UCL signs Ophthalmology MoU
30 Sep 2016 by Evoluted New Media
UCL and Santen have signed a Memorandum of Understanding (MoU) to collaborate on ophthalmic research and education.
UCL and Santen have signed a Memorandum of Understanding (MoU) to collaborate on ophthalmic research and education.
Santen will conduct research programs with scientists in the UCL Institute of Ophthalmology and also provide PhD student with funding support. This MoU will allow both Santen and UCL to collaborate on ophthalmic research, turning this into therapeutic measures that can be applied to patients.
Naveed Shams, Chief Scientific Officer at Santen, said: “I believe this partnership will facilitate our exploration activity to achieve our R&D strategic goals through collaboration in clinical research, translational research and disease-targeted drug discovery. By leveraging this robust partnership, Santen will be continuously seeking innovative therapeutic opportunities and technology platforms that visualize and fulfil future unmet medical needs in the ophthalmology space.”
The framework established by the MoU will allow both parties to work together on capability and talent development in varying fields of ophthalmology. The Memorandum was signed by Shams and Dr Celia Caulcott, Vice-Provost at UCL.
Dr Caulcott said: “UCL is delighted to sign this collaboration agreement with Santen, a world leading ophthalmic pharmaceutical company. This agreement underpins our relationship, which will help accelerate the translation of UCL’s world-class research into new medical treatments. It exemplifies UCL’s Grand Challenges strategy which looks to bring expertise from UCL and beyond together to solve global health problems.”
Santen is a Japanese company that provides prescription ophthalmic pharmaceuticals. The partnership was supported by UCL Business PLC, a technology transfer company for innovation and research from UCL.
